CytRx Corp (CYTR):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10116)
◆英語タイトル:CytRx Corp (CYTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10116
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
CytRx Corp (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company’s oncology based product comprises of its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of the commonly prescribed chemotherapeutic doxorubicin, designed to reduce adverse events by controlling release and preferentially targeting the tumor. Its other new albumin-binding drug conjugates are under pre-clinical development. The company conducts discovery and translational research at its discovery laboratory located in Freiburg, Germany. It has a strategic alliance with KTB Tumorforschungs GmbH. CytRx is headquartered in Los Angeles, California, the US.

CytRx Corp (CYTR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CytRx Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CytRx Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CytRx Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CytRx Raises USD1.3 Million in Financing 11
Licensing Agreements 12
NantCell Enters into Licensing Agreement with CytRx 12
Equity Offering 13
CytRx Raises USD7 Million in Private Placement of Shares 13
CytRx Plans to Raise up to USD0.2 Million in Public Offering of Shares 15
CytRx Prices Public Offering of Shares for USD15 Million 16
CytRx to Raise USD8 Million in Private Placement of Shares 17
CytRx Raises USD20 Million in Public Offering of Shares 19
CytRx Raises USD28.8 Million in Public Offering of Shares 20
CytRx Completes Public Offering Of Shares For US$86 Million 22
CytRx Completes Public Offering Of Shares For US$26 Million 23
CytRx Completes Public Offering Of Common Stock For US$23 Million 24
CytRx Corp – Key Competitors 25
CytRx Corp – Key Employees 26
CytRx Corp – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Strategy And Business Planning 28
Jun 04, 2018: CytRx Launches Centurion BioPharma to Advance LADR Albumin Binding Ultra-High Potency Oncology Drug Candidates 28
Financial Announcements 29
Aug 06, 2018: CytRx Reports Second Quarter 2018 Financial Results 29
May 08, 2018: CytRx announces First Quarter 2018 Financial Results 31
Mar 19, 2018: CytRx Announces 2017 Financial Results 33
Nov 08, 2017: CytRx Reports Third Quarter 2017 Financial Results 35
Aug 03, 2017: CytRx Reports Second Quarter 2017 Financial Results 37
May 10, 2017: CytRx Reports First Quarter 2017 Financial Results 39
Mar 15, 2017: CytRx Reports 2016 Financial Results 41
Corporate Communications 43
Jun 25, 2018: CytRx joins Russell Microcap Index 43
May 03, 2018: CytRx Names Eric L. Curtis as Its President and Chief Operating Officer 44
Oct 16, 2017: CytRx announces outcome of Nasdaq hearing 45
Aug 24, 2017: CytRx announces receipt of NASDAQ listing determination 46
Jun 13, 2017: CytRx Announces Reshaping of Clinical and Regulatory Executive Team 47
Product News 48
Mar 15, 2018: CytRx Selects Four New LADR Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials 48
Clinical Trials 50
Mar 26, 2018: UMass Medical School HIV vaccine to be tested in new Phase I trial 50
Other Significant Developments 51
Nov 13, 2017: CytRx Provides Business Update and Announces New Shareholder Initiatives 51
Nov 06, 2017: CytRx Announces Strategic Realignment of Clinical Development Team 52
Nov 02, 2017: CytRx Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology Pipeline 53
Oct 02, 2017: CytRx Provides Business Update and Highlights Future Plans 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
CytRx Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CytRx Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CytRx Corp, Deals By Therapy Area, 2012 to YTD 2018 9
CytRx Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CytRx Raises USD1.3 Million in Financing 11
NantCell Enters into Licensing Agreement with CytRx 12
CytRx Raises USD7 Million in Private Placement of Shares 13
CytRx Plans to Raise up to USD0.2 Million in Public Offering of Shares 15
CytRx Prices Public Offering of Shares for USD15 Million 16
CytRx to Raise USD8 Million in Private Placement of Shares 17
CytRx Raises USD20 Million in Public Offering of Shares 19
CytRx Raises USD28.8 Million in Public Offering of Shares 20
CytRx Completes Public Offering Of Shares For US$86 Million 22
CytRx Completes Public Offering Of Shares For US$26 Million 23
CytRx Completes Public Offering Of Common Stock For US$23 Million 24
CytRx Corp, Key Competitors 25
CytRx Corp, Key Employees 26
CytRx Corp, Subsidiaries 27

List of Figures
CytRx Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CytRx Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ CytRx Corp (CYTR):製薬・医療:M&Aディール及び事業提携情報(CytRx Corp (CYTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆